SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study

Background SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a candidate contributor to airway inflammation and remodeling. We explored associations between the SERPINE1 −675 4G/5G polymorphism and outcomes during tezepelumab treatment. Methods This prospective multicenter cohort enrolled 45 Japanese adults; 44 completed 52 weeks (4G/4G, 21; 4G/5G, 15; 5G/5G, 8). Genotyping of pretreatment samples occurred after follow-up, with physicians and outcome assessors blinded to genotype. The approved protocol specified negative binomial regression comparing 4G carriers with 5G/5G, adjusted for prior-year exacerbations. Additional adjustment for prior biologic exposure, ICS category, and maintenance OCS use was retained as exploratory. Results Forty-seven exacerbations occurred over 44 patient-years, defining one analysis year as 52 weeks. Crude annualized exacerbation rates were 1.14, 0.73, and 1.50 events/patient-year across the three genotypes; 30 participants had no exacerbations. The protocol-specified adjusted incidence rate ratio was 5.06 (95% confidence interval, 0.51–49.97), compared with 0.65 (0.11–3.69) unadjusted and 3.28 (0.34–31.29) with expanded adjustment. These estimates were too imprecise and model-dependent for reliable interpretation. An exploratory three-genotype FeNO comparison at week 52 yielded P = 0.00353; post hoc false discovery rate adjustment gave q = 0.04594 across 13 secondary tests and q = 0.08127 across 23 secondary/exploratory tests. The 0.05 threshold was met only in the smaller family; both adjustments remain exploratory. Conclusions The data do not establish either a clinically useful genotype association or its absence. Sparse outcomes, baseline imbalance, and heterogeneous treatment histories limit inference. Without a comparator treatment, this study cannot determine whether genotype modifies the treatment effect of tezepelumab. Trial registration: UMIN000052531, October 18, 2023.

Authors

Institutions

Publication Details

Journal
Frontiers in Allergy
Published
2026-11-20
DOI
https://doi.org/10.3389/falgy.2026.2016157
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study

Hiromi Ide, Norio Kodaka, 和子 山本, Shusaku Haranaga et al.
2 links
Frontiers in Allergy
Asthma and respiratory diseases
article

SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study

Hiromi Ide, Norio Kodaka, 和子 山本, Shusaku Haranaga, Wakako Arakaki, Hironobu Tsubouchi, Nobuhiro Matsumoto, Ayako Matsuo, 慎也 泊, Hiroki Tashiro, Nobuko Matsuo, Hideki Sakakibara, Chizu Fukushima, Koichiro Takahashi, Kazunori Tobino, Kosuke Kosai, Katsunori Yanagihara, Hiroto Matsuse, Kazuhiro Yatera, Hiroshi Mukae, Taiga Miyazaki, Susumu Fukahori, Daisuke Himeji, Hiroyuki Yoshimine, Yasushi Obase, Shintaro Hara
article en

Abstract

Background SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a candidate contributor to airway inflammation and remodeling. We explored associations between the SERPINE1 −675 4G/5G polymorphism and outcomes during tezepelumab treatment. Methods This prospective multicenter cohort enrolled 45 Japanese adults; 44 completed 52 weeks (4G/4G, 21; 4G/5G, 15; 5G/5G, 8). Genotyping of pretreatment samples occurred after follow-up, with physicians and outcome assessors blinded to genotype. The approved protocol specified negative binomial regression comparing 4G carriers with 5G/5G, adjusted for prior-year exacerbations. Additional adjustment for prior biologic exposure, ICS category, and maintenance OCS use was retained as exploratory. Results Forty-seven exacerbations occurred over 44 patient-years, defining one analysis year as 52 weeks. Crude annualized exacerbation rates were 1.14, 0.73, and 1.50 events/patient-year across the three genotypes; 30 participants had no exacerbations. The protocol-specified adjusted incidence rate ratio was 5.06 (95% confidence interval, 0.51–49.97), compared with 0.65 (0.11–3.69) unadjusted and 3.28 (0.34–31.29) with expanded adjustment. These estimates were too imprecise and model-dependent for reliable interpretation. An exploratory three-genotype FeNO comparison at week 52 yielded P = 0.00353; post hoc false discovery rate adjustment gave q = 0.04594 across 13 secondary tests and q = 0.08127 across 23 secondary/exploratory tests. The 0.05 threshold was met only in the smaller family; both adjustments remain exploratory. Conclusions The data do not establish either a clinically useful genotype association or its absence. Sparse outcomes, baseline imbalance, and heterogeneous treatment histories limit inference. Without a comparator treatment, this study cannot determine whether genotype modifies the treatment effect of tezepelumab. Trial registration: UMIN000052531, October 18, 2023.

Frontiers in AllergyVol. 7
University of Miyazaki (JP), Saga University (JP), University of Occupational and Environmental Health Japan (JP), University of the Ryukyus (JP), Inoue Hospital (JP), Toho University Ohashi Medical Center (JP), Miyazaki Prefectural Hospital (JP), Nagasaki Medical Center (JP), Japan Community Healthcare Organization (JP), National Hospital Organization Miyazaki Higashi Hospital (JP), Aso Iizuka Hospital (JP), University of the Ryukyus University Hospital (JP), Nagasaki University Hospital (JP), Nagasaki University (JP), Isahaya General Hospital (JP)
Good health and well-being
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon